Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy-Reference-Cited by-同舟云学术

Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy

Published:2018-04-23 Issue:1 Volume:122 Page:89-98
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Mmeje Chinedu O.¹,Benson Cooper R.¹^ORCID,Nogueras-González Graciela M.²,Jayaratna Isuru S.¹,Gao Jianjun³,Siefker-Radtke Arlene O.³,Kamat Ashish M.¹,Dinney Colin P.¹,Navai Neema¹,Shah Jay B.⁴

Affiliation:

1. Department of Urology; The University of Texas M.D. Anderson Cancer Center; Houston TX USA

2. Department of Genitourinary Medical Oncology; The University of Texas M.D. Anderson Cancer Center; Houston TX USA

3. Department of Biostatistics; The University of Texas M.D. Anderson Cancer Center; Houston TX USA

4. Department of Urology; Stanford University; Palo Alto CA USA

Funder

Cancer Center Support Grant

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14211/fullpdf

Reference28 articles.

1. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients;Stein;J Clin Oncol,2001

2. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration;Advanced Bladder Cancer (ABC) Meta-analysis Collaboration;Eur Urol,2005

3. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman;N Engl J Med,2003

4. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study;Gandaglia;Eur Urol,2014

5. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924;Sternberg;J Clin Oncol,2001

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dose‐dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle‐invasive bladder cancer;International Journal of Urology;2024-07-03

2. Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes;Urologic Oncology: Seminars and Original Investigations;2024-04

3. Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer;BMC Cancer;2024-01-31

4. Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience;Clinical and Translational Oncology;2023-08-11

5. Impacto clínico de no aplicar el protocolo ERAS en los pacientes sometidos a cistectomía durante la pandemia COVID-19;Actas Urológicas Españolas;2023-07